HTA Database - Search Results

Sort by Relevance

Search Results [15895 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2009	The Regional Health Technology Assessment Centre (HTA-centrum)	[Robotic assisted laparoscopic surgery for cervical and endometrial cancer]
2009	The Regional Health Technology Assessment Centre (HTA-centrum)	[Urgent or late carotid endarterectomy in patients with symptomatic stenosis of the internal carotid artery]
2009	The Regional Health Technology Assessment Centre (HTA-centrum)	[Auricular acupuncture for narcotic dependency]
2009	The Regional Health Technology Assessment Centre (HTA-centrum)	[Immunoglobulin in patients with post-polio syndrome]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®) for the treatment of HIV-1 infected, treatment-naïve adults in combination with other antiretroviral medicinal products
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Degarelix (Firmagon®) for the treatment of advanced hormone-dependent prostate cancer
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ranolazine (Ranexa®) as add-on therapy for symptomatic treatment of stable angina pectoris
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Methoxy polyethylene glycol-epoetin beta (Mircera®)
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Mecasermin (Increlex®)
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Filgrastim (Ratiograstim®) for the treatment of neutropenia
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Etravirine (Intelence®) for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Paricalcitol (Zemplar®) capsules for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Micafungin (Mycamine®) for the treatment of invasive candidiasis in adults and children
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Bivalirudin (Angiox®) for the treatment of adult patients with acute coronary syndromes planned for urgent or early intervention
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Advagraf®) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Aliskiren (Rasilez®) for the treatment of essential hypertension
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ambrisentan (Volibris®) for pulmonary arterial hypertension
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Maraviroc (Celsentri®) for treatment-experienced adults infected only with CCR5-tropic HIV-1
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Anidulafungin (Ecalta®) for the treatment of invasive candidiasis in adult non-neutropenic patients
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Nelarabine (Atriance®) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) for the treatment of HIV-1 infection in adults
2009	NIHR Health Technology Assessment programme	Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal
2009	Institute of Health Economics (IHE)	Human papillomavirus (HPV) testing in Alberta
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[New treatment with avastin and alimta for patients with non-small cell lung cancer]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Patient education - a health technology assessment]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Screening for haemoglobin disorders among pregnant immigrants – a health technology assessment summary]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Selfmonitored anticoagulant therapy]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Shared care in catheterization of patients with long-term urinary catheter need]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Health economic analysis of diagnostic strategies of colorectal cancer - a health technology assessment]
2009	Technology Assessment at SickKids (TASK)	Systematic review on orchidopexy for the Canadian Paediatric Surgical Wait Times project
2009	Health Technology and Policy Unit (HTPU)	Photodynamic therapy for the treatment of early esophageal cancer: a systematic review and economic evaluation
2009	Health Technology and Policy Unit (HTPU)	Photodynamic therapy for the treatment of barrett's esophagus: a systematic review and economic evaluation
2009	NIHR Health Technology Assessment programme	Telbivudine for the treatment of chronic hepatitis B infection
2009	NIHR Health Technology Assessment programme	Entecavir for the treatment of chronic hepatitis B infection
2009	NIHR Health Technology Assessment programme	Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
2009	NIHR Health Technology Assessment programme	Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
2009	NIHR Health Technology Assessment programme	Ustekinumab for the treatment of moderate to severe psoriasis
2009	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Technologies for the identification of osteoporosis
2009	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Prostheses for primary total knee replacement in Italy
2009	NIHR Health Technology Assessment programme	Gemcitabine for the treatment of metastatic breast cancer
2009	NIHR Health Technology Assessment programme	Varenicline in the management of smoking cessation: a single technology appraisal
2009	NIHR Health Technology Assessment programme	Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal
2009	NIHR Health Technology Assessment programme	Rituximab for the treatment of rheumatoid arthritis
2009	NIHR Health Technology Assessment programme	Omalizumab for the treatment of severe persistent allergic asthma
2009	NIHR Health Technology Assessment programme	Adalimumab for the treatment of psoriasis
2009	NIHR Health Technology Assessment programme	Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal
2009	NIHR Health Technology Assessment programme	Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer
2009	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2009	NIHR Health Technology Assessment programme	Docetaxel for the adjuvant treatment of early breast cancer
2009	National Evidence-based Healthcare Collaborating Agency (NECA)	[Reuse of single-use medical devices: current evidence and regulations]
2009	University of York	Cognitive behaviour therapy for schizophrenia
2009	University of York	Physical health monitoring for people with schizophrenia or other serious mental illness
2009	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	Implantable device for the treatment of drug-resistant hypertension
2009	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Overweight prevention in adolescents and children (behavioural and environmental prevention]
2009	Haute Autorite de sante (HAS)	[Assessment of breast implants, tissue expanders and external breast prostheses]
2009	Haute Autorite de sante (HAS)	[Assessment of drug-eluting stents]
2009	Health Sciences Institute in Aragon (IACS)	Diabetes complications. Diabetic nephropathy
2009	Health Sciences Institute in Aragon (IACS)	Diabetes complications. Diabetic retinopathy
2009	Canary Health Service	[Appropriateness in the indication of physical therapy techniques for cervical pain, low back pain and chronic shoulder pain of non-specific origin]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Follow-up in gynaecological cancer patients - a health technology assessment]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	National strategi for medicinsk teknologivurdering - Bedre grundlag for planlægning og prioritering for sundhedsområdet
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis on depression]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Non-drug therapies in Alzheimer's disease]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Long-acting insulin analogues in the treatment of diabetes mellitus type 2]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Clopidogrel plus acetylsalicylic acid in acute coronary syndrome]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Different antihypertensive drugs as first-line therapy in patients with essential hypertension]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Systematic guideline search and appraisal for the DMP "Obesity"]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Interventions in young children with obstructive airway diseases]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Positron emission tomography (PET) in malignant lymphoma]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glinides in the treatment of diabetes mellitus type 2]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Decompression for carpal tunnel syndrome" - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Conization of the cervix uteri" - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Cataract surgery" -Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Surgery for varices" - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relevance of the condition of the opposite dentition when fitting a fixed or removable denture]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Reduction of salt intake in essential hypertension - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Scientific evaluation of different investigational methods used in diagnosing "bronchial asthma" in children aged 2 to 5 years]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for defined speech and language development disorders in children]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for gestational diabetes]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Memantine in Alzheimer's disease]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implant-supported supraconstructions for the treatment of shortened dental arches]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Quality of haematological and oncological care in children]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Autologous stem cell transplantation for soft tissue sarcoma]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Autologous stem cell transplantation for breast cancer]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Urine and blood glucose self-measurement in diabetes mellitus type 2]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rapid-acting insulin analogues in children and adolescents with diabetes mellitus type 1 - follow-up commission]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Update search on Report A05-19A (cholinesterase inhibitors in the treatment of Alzheimer's Disease) - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bupropion, mirtazapine, and reboxetine in the treatment of depression]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Non-drug local procedures for treatment of benign prostatic syndrome - Update - rapid report]
2009	National Institute for Health and Care Excellence (NICE)	Radiofrequency ablation for colorectal liver metastases. NICE interventional procedures guidance 327
2009	National Institute for Health and Care Excellence (NICE)	Suction diathermy adenoidectomy. NICE interventional procedures guidance 328
2009	National Institute for Health and Care Excellence (NICE)	Balloon catheter insertion for Bartholin's cyst or abscess. NICE interventional procedures guidance 323
2009	National Institute for Health and Care Excellence (NICE)	Electrocautery cutting balloon treatment for pelviureteric junction obstruction. NICE interventional procedures guidance 324
2009	National Institute for Health and Care Excellence (NICE)	Endopyelotomy for pelviureteric junction obstruction. NICE interventional procedures guidance 325